Gene-expression signatures in breast cancer.

By P. Helmbold, J. Haerting, H. Kölbl. New England Journal of Medicine, 2003

1,033 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/8e80fdd73ef7dc740b9857c1893514400bca7aad

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

An overview of triple-negative breast cancer (2016, unknown): “HER2 gene [12].”
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 (2009, background): “Gene expression signatures are likely to indicate a prognostically relevant dichotomy (low grade versus high grade), though the implications of this observation for therapy require further study [87, 88].”
Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome (2011, background): “Yet, proliferation-related signals are prognostic mostly in ER+ tumors [1].”
The Influence of Feature Selection Methods on Accuracy, Stability and Interpretability of Molecular Signatures (2011, background): “…investigated so-called molecular signatures , i.e., predictive models based on the expression of a small number of genes, for the stratiﬁcation of early breast cancer patients into low-risk or high-risk of relapse, in order to guide the need for adjuvant therapy (Sotiriou and Pusztai, 2009).”
The immune contexture in human tumours: impact on clinical outcome (2012, background): “Data based on immune signatures have established that a strong immune cell component is predictive of a good response to chemotherapy in breast cance”
A Molecular Taxonomy for Urothelial Carcinoma (2012, background): “for, for example, breast cancer in which 4 main classes of tumors have been defined; luminal A, luminal B, HER2enriched, and basal-like, which show different clinical outcomes (13, 14).”
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. (2013, unknown): “Initially, prognostic molecular signatures focused on the malignant cell, improving BC taxonomy via the assessment of genes regulating the cell cycle and proliferation (3, 4).”
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer (2011, background): “Expression profiling of breast cancer has shown that vimentinexpressing cancers are mesenchymal or Basal B type (Neve et al., 2006; Sarrio et al., 2008; Sotiriou and Pusztai, 2009).”
Breast cancer intrinsic subtype classification, clinical use and future trends. (2015, methodology): “Commercially available prognostic multi-gene signatures for breast cancer patients [6, 54]”
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors (2011, background): “Recently, several molecular tests for prediction of breast cancer prognosis have been developed in order to aid clinical decision making (3-5).”
Rank–rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures (2010, background): “Tumors that have loss of all of these markers (‘triple-negative’) are associated with the ‘basal-like’ gene expression-based subclass of breast tumors and with poor prognosis (23).”